ArticleScientific reports2026
Assessing mortality risk in pulmonary tuberculosis and severe malnutrition: development of the IIR marker via artificial intelligence.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sarcopenia in Inflammatory Bowel Disease: Prevalence, Mechanisms, Detection, Adverse Clinical Impact and Targetable Care Gaps-A Narrative Review Supported by a Structured Literature Search.Life (Basel, Switzerland) · 2026Review
- New Strategies in Tuberculosis Prediction: TB-CAST, an Explainable Baseline Score for Two-Month Sputum Culture Positivity.Life (Basel, Switzerland) · 2026Article
- Assessing mortality risk in pulmonary tuberculosis and severe malnutrition: development of the IIR marker via artificial intelligence.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The early identification of mortality risk in patients with tuberculosis (TB) and severe malnutrition (BMI <16 kg/m2) is critical for optimizing clinical outcomes. In this three-year ambispective study (October 1, 2021–September 30, 2024), conducted at Leamna Hospital, a reference center for the Oltenia Region, Romania, 216 patients with pulmonary tuberculosis were selected from a total of 3,547 TB cases for analysis. We assessed all-cause in-hospital mortality during the index admission only (from admission to discharge); deaths after discharge or during subsequent admissions were excluded, patients transferred without cross-facility linkage were right-censored at transfer, and all analyses used baseline hematological and biochemical parameters obtained before initiation of any treatment. We developed and validated the Immuno-Inflammatory Ratio (IIR), a novel machine-learning–assisted biomarker integrating neutrophils, lymphocytes, and eosinophils. The IIR demonstrated an apparent AUC of 0.9711 with an optimal threshold of 7.44 (sensitivity 99.40%, specificity 91.49%). In regression analyses, the IIR emerged as the strongest independent predictor of mortality (adjusted OR 13.98, p < 0.001), outperforming established indices such as the neutrophil-to-lymphocyte ratio (NLR) and the cumulative inflammatory index (IIC). Given its simplicity and strong discriminatory power, the IIR may support early risk stratification and prioritization of standard interventions (e.g., intensified monitoring, nutritional support, and timely optimization of anti-TB therapy). Prospective multicenter validation and longitudinal assessment of IIR dynamics are warranted to confirm clinical utility and define applications beyond the index admission, including in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.